论文部分内容阅读
目的了解浙江省永康市第一人民医院2011—2014年核苷酸类药物的使用情况,包括用药金额和用药频度(DDDs)。方法统计浙江省永康市第一人民医院2011—2014年拉米夫定、阿德福韦酯、替比夫定、恩替卡韦的用药金额、用药频度以及排名情况。结果各个用药金额逐年增长,其中恩替卡韦增长最为显著,虽然替比夫定在年增长量上有很大突破但该药品的DDDs一直处于最小,拉米夫定和阿德福韦酯的增长状态较为稳定。结论抗病毒治疗是慢性乙型肝炎治疗的关键,必须严格掌握治疗适应证,谨慎选择核苷酸类药物制定一个合理的治疗方案。
Objective To understand the usage of nucleotide drugs in 2011-2014 in First People’s Hospital of Yongkang City, Zhejiang Province, including the amount of medication and frequency of DDDs. Methods The amount of medication, frequency of medication and rankings of lamivudine, adefovir dipivoxil, telbivudine and entecavir from 2011 to 2014 in First People’s Hospital of Yongkang City, Zhejiang Province were calculated. Results The amount of each drug used increased year by year, with the most significant increase of entecavir. Although telbivudine had a great breakthrough in the annual growth rate, the DDDs of the drug had been kept at the minimum. The growth status of lamivudine and adefovir dipivoxil was more stable. Conclusion Antiviral therapy is the key to the treatment of chronic hepatitis B. It is necessary to strictly control indications for treatment and carefully select nucleotide drugs to formulate a reasonable treatment plan.